Related Image: VendorClear™ Introduces Revolutionary Products for Healthcare Facilities and Vendor Representatives |
(Date:11/21/2008)...PRNewswire/ -- NursingCenter.com, the premier site... reviewed content, has been,updated to improve th...d,users. Powered by Lippincott Williams & Wil...00 peer-reviewed continuing education activities a...50 leading nursing journals.,Lippincott Williams ...
(Date:11/21/2008)...wswire/ -- The general membership of the Medical,... individuals at their Annual,Awards Dinner to be ...York. A,Lifetime Achievement Award will also be g... Advertising Hall of Fame are: , Ronald Pantell...t position,at Sudler & Hennessey. In 1980 he ...
(Date:11/21/2008)...rugs do not cause genetic damage that can lead to ...ews) -- Two popular medications for treating atten...cause genetic damage linked to an increased risk f...tudy, done by researchers at Duke University Medic...ounters a previous one that reported biomarkers as...
(Date:11/21/2008)...wire/ -- In a statewide survey, 33 physicians cred...rgery at Presbyterian Hospital of Dallas were hono...of " Super Doctors ." , , Each year, the pu...onal Media, Inc. to survey more than 38,000 medica..."If you needed medical care, which doctor would yo...
Breaking Medicine News(10 mins):Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2(Date:11/20/2008)...LE, Calif., Nov. 20 Bion... will present results from the Phase 1B,clinical ...tastatic breast,cancer, BZL101, at the Society fo...erence in Atlanta, Georgia. The Company,s oral pr... and will be presented as a part of the Best of th...
(Date:11/20/2008)...SO, Norway, November 20 The Scandi...arma has announced results of studies on its,lead...AC in Washington, DC,the studies showed that the...cteriocidal effect, significantly better towards k...ogenes than marketed gold standard drugs. In,addi...
(Date:11/19/2008)...ELLE, N.Y., Nov. 19 Biotech scient...es to toxicology research to better understand the...organ systems, reports Genetic Engineering & ...nterested in figuring out a new compound,s mechani...e toxicology technique, according to the November ...
(Date:11/18/2008)... Pa., Nov. 18 Arlington Medical Re...ligence for the pharmaceutical and diagnostic,ima...L Behring,s Privigen was,sold in the U.S. during ...,brand of intravenous immune globulin (IVIG) and w... a product created from the blood plasma of thousa...
Breaking Medicine Technology:Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2Cardiome Reports First Quarter Results 19236 1Cardiome Reports First Quarter Results 19236 2Cardiome Reports First Quarter Results 19236 3Cardiome Reports First Quarter Results 19236 4Cardiome Reports First Quarter Results 19236 5Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 1Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 2Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 3Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 4Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 5Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 6Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 7Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 8Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 9Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 10Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 11Amicus Therapeutics Announces First Quarter 2008 Financial Results 5365 12Sigma Aldrich Recognized by BioInformatics LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs 5361 1Sigma Aldrich Recognized by BioInformatics LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs 5361 2Sigma Aldrich Recognized by BioInformatics LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs 5361 3Quality Lags at Safety Net Hospitals 19232 1Quality Lags at Safety Net Hospitals 19232 2Quality Lags at Safety Net Hospitals 19232 3..., 2007 /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. ...elanoma vaccine clinical trial and data from the P... vaccine clinical trial will be,presented at the 2...3rd annual meeting in Chicago on June 1-5 2007. , ...cal and immunological responses in patients with m...
...e Patients Receiving Combination of,Bavituximab Pl...sponse or Stable Disease - , - 75% of Patients ...ine , ,Achieved Objective Tumor Response...Receiving Combination of Bavituximab Plus , ... Response - , - Trial Results Support Advanc...
Other Medicine Technology:IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 2IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 3IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 4IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 5IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting 6Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 2Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 3Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 4Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 5More than 200 key diagnostic and treatment tables culled from Tierney's Current Medical Diagnostics and Treatment 2003.
Athouritative, on the spot answers for acute care and consultations.
...de includes a specially designed, integrated retra... and handling. The Xstar Blade technology is base...al blades. This proprietary process yields outsta...single-bevel geometry allows the surgeon to create...
...de includes a specially designed, integrated retra... and handling. The Xstar Blade technology is base...al blades. This proprietary process yields outsta...single-bevel geometry allows the surgeon to create...
Medicine Products: